Boston Scientific Concludes Enrollment In Randomized, Multicenter, Pivotal Study Of SYNERGY™ Coronary Stent System (via PR Newswire)NATICK, Mass., Sept. 12, 2013 /PRNewswire/ — In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II randomized…
